EUVIMEDEUVIMED entdecken
Crossref

Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR

Shuang Yang, Yixiu Zhao, Shifeng Cao, Xinxin Liu, Min Feng, Yi Chen, Chunyue Ma, Tingting Zhan, Qi Zhang, Honglin Jia, Yu Zhao, Ming Tong und 4 weitere

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2024.155704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Shuang Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Labratoray -Province Key Laboratories of…. Hauptthemen laut MEDLINE: Anthraquinones, Cell Dedifferentiation, Kruppel-Like Factor 4, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, Chinese Academy of Meteorological Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dysregulation of vascular smooth muscle cell (VSMC) function leads to a variety of diseases such as atherosclerosis and hyperplasia after injury. However, antiproliferative drug targeting VSMC exhibits poor specificity. Therefore, there is an urgent to develop highly specific antiproliferative drugs to prevention and treatment VSMC dedifferentiation associated arteriosclerosis. Kanglexin (KLX), a new anthraquinone compound designed by our team, has potential to regulate VSMC phenotype according to the physicochemical properties. PURPOSE: This project aims to evaluate the therapeutic role of KLX in VSMC dedifferentiation and atherosclerosis, neointimal formation and illustrates the underlying molecular mechanism. METHODS: In vivo, the ApoE-/- mice were fed with high-fat diet (HFD) for a duration of 13 weeks to establish the atherosclerotic model. And rat carotid artery injury model was performed to establish the neointimal formation model. In vitro, PDGF-BB was used to induce VSMC dedifferentiation. RESULTS: We found that KLX ameliorated the atherosclerotic progression including atherosclerotic lesion formation, lipid deposition and collagen deposition in aorta and aortic sinus in atherosclerotic mouse model. In addition, The administration of KLX effectively ameliorated neointimal formation in the carotid artery following balloon injury in SD rats. The findings derived from molecular docking and surface plasmon resonance (SPR) experiments unequivocally demonstrate that KLX had potential to bind PDGFR-β. Mechanism research work proved that KLX prevented VSMC proliferation, migration and dedifferentiation via activating the PDGFR-β-MEK -ERK-ELK-1/KLF4 signaling pathway. CONCLUSION: Collectively, we demonstrated that KLX effectively attenuated the progression of atherosclerosis in ApoE-/- mice and carotid arterial neointimal formation in SD rats by inhibiting VSMC phenotypic conversion via PDGFR-β-MEK-ERK-ELK-1/KLF4 signaling. KLX exhibits promising potential as a viable therapeutic agent for the treatment of VSMC phenotype conversion associated arteriosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthraquinonesCell DedifferentiationKruppel-Like Factor 4Muscle, Smooth, VascularNeointimaAnimalsMaleMiceRatsArteriosclerosisAtherosclerosisBecaplerminCarotid Artery InjuriesCell ProliferationDiet, High-FatDisease Models, AnimalKruppel-Like Transcription FactorsMice, Inbred C57BLMolecular Docking SimulationMyocytes, Smooth MuscleRats, Sprague-DawleyReceptors, Platelet-Derived Growth FactorSignal Transduction

Stichwörter der Autor:innen

AtherosclerosisNeointimal hyperplasiaPDGFR-βPhenotypic switchingVSMC

Substanzen

AnthraquinonesBecaplerminKLF4 protein, humanKlf4 protein, mouseKlf4 protein, ratKruppel-Like Factor 4Kruppel-Like Transcription FactorsReceptors, Platelet-Derived Growth Factorkanglexin

Autor:innen und Institutionen

  • State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Labratoray -Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular…

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • Chinese Academy of Meteorological Sciences

Zitieren

APA

Yang, S., Zhao, Y., Cao, S., Liu, X., Feng, M., Chen, Y., Ma, C., Zhan, T., Zhang, Q., Jia, H., Zhao, Y., Tong, M., Yu, Y., Liu, X., Yang, B., & Zhang, Y. (2024). Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155704

Vancouver

Yang S, Zhao Y, Cao S, Liu X, Feng M, Chen Y, et al. Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155704

BibTeX
@article{Yang2024,
  author = {Yang, Shuang and Zhao, Yixiu and Cao, Shifeng and Liu, Xinxin and Feng, Min and Chen, Yi and Ma, Chunyue and Zhan, Tingting and Zhang, Qi and Jia, Honglin and Zhao, Yu and Tong, Ming and Yu, Yuanyuan and Liu, Xue and Yang, Baofeng and Zhang, Yan},
  title = {Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2024.155704}
}
Kostenlos starten →